Cogent Biosciences (COGT) vs Erasca (ERAS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Erasca (ERAS) has outperformed Cogent Biosciences (COGT) over the past year, gaining 536.2% versus a gain of 93.1%. Over five years, COGT leads with a +225.5% price change compared with -13.1% for ERAS. Erasca is the larger company by market cap ($5.41 billion vs $5.22 billion), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | COGT | ERAS |
|---|---|---|
| Share price | $30.08 | $15.46 |
| Market cap | $5.22B | $5.41B |
| 1-day change | -0.20% | +9.49% |
| YTD return | -15.32% | +315.59% |
| 1-year return | +93.07% | +536.21% |
| 5-year return | +225.54% | -13.15% |
| EPS (TTM) | $-2.16 | $-0.95 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | $-328.94M | $-124.55M |
| 52-week high | $43.73 | $24.28 |
| 52-week low | $13.78 | $2.11 |
| Distance from 52-week high | -31.21% | -36.33% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +85.57% | +55.95% |
| Average volume | 1.90M | 4.37M |
| Shares outstanding | 173.52M | 349.76M |
| Employees | 258 | 103 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ERAS has outperformed COGT by 443.1 percentage points over the past year.
About Cogent Biosciences
COGT stock →Cogent Biosciences, Inc., a clinical-stage biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor in Phase 3 trial designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors.
Health Care · Biotechnology: Pharmaceutical Preparations · 258 employees
About Erasca
ERAS stock →Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes ERAS-0015, a pan-RAS molecular glue for the treatment of patients with RAS-mutated solid tumors; ERAS-4001, a pan-KRAS inhibitor for the treatment of patients with KRAS-mutated solid tumors; and ERAS-12, an investigational EGFR D2/D3 biparatopic antibody (bpAb) for the treatment of EGFR and RAS/MAPK solid tumors.
Health Care · Biotechnology: Pharmaceutical Preparations · 103 employees
COGT vs ERAS FAQ
Which is bigger, Cogent Biosciences or Erasca?
Erasca (ERAS) is larger, with a market capitalization of $5.41B compared with $5.22B for Cogent Biosciences (COGT).
Which stock has performed better over the past year, COGT or ERAS?
ERAS returned +536.21% over the past 12 months, compared with +93.07% for COGT (price return, excluding dividends). Past performance does not predict future results.
Are Cogent Biosciences and Erasca in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.